BridgeBio Oncology Therapeutics Ord Shs
BBOT12.180USD
-0.340-2.72%
Close 12/22, 16:00（ET）Quotes delayed by 15 min
286.34MMarket Cap
60.33P/E TTM
More Details of Company
BridgeBio Oncology Therapeutics Ord Shs Info
Ticker Symbol- -
Company name- -
IPO date- -
CEO- -
Number of employees- -
Security type- -
Fiscal year-end- -
Address- -
City- -
Stock exchange- -
Country- -
Postal code- -
Phone- -
Website- -
Ticker Symbol- -
IPO date- -
CEO- -
Company Executives of BridgeBio Oncology Therapeutics Ord Shs
Name
Name/Position
Position
Shareholding
Change
,
,
--
--
Name
Name/Position
Position
Shareholding
Change
,
,
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Wed, Dec 10
Updated: Wed, Dec 10
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Cormorant Asset Management, LP
22.35%
BridgeBio Pharma, Inc.
18.24%
Deerfield Management Company, L.P.
6.11%
BC Global Opportunities IX LP
5.46%
Omega Fund Management, LLC
4.11%
Other
43.73%
Shareholders
Shareholders
Proportion
Cormorant Asset Management, LP
22.35%
BridgeBio Pharma, Inc.
18.24%
Deerfield Management Company, L.P.
6.11%
BC Global Opportunities IX LP
5.46%
Omega Fund Management, LLC
4.11%
Other
43.73%
Shareholder Types
Shareholders
Proportion
Hedge Fund
41.69%
Corporation
26.98%
Investment Advisor/Hedge Fund
10.78%
Venture Capital
10.12%
Investment Advisor
5.17%
Research Firm
0.26%
Individual Investor
0.11%
Other
4.88%
Institutional Shareholding
Updated: Tue, Dec 9
Updated: Tue, Dec 9
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
73
54.44M
68.05%
+15.73M
2025Q3
72
54.42M
68.03%
+15.72M
2025Q2
49
16.72M
87.47%
-855.66K
2025Q1
43
16.79M
88.78%
-267.82K
2024Q4
41
16.75M
88.56%
+227.86K
2024Q3
36
16.37M
86.59%
-5.42K
2024Q2
33
16.38M
89.02%
+311.06K
2024Q1
31
16.07M
84.98%
+7.80M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Cormorant Asset Management, LP
17.88M
22.35%
--
--
Sep 30, 2025
BridgeBio Pharma, Inc.
13.81M
17.43%
+13.81M
--
Aug 29, 2025
Deerfield Management Company, L.P.
4.89M
6.11%
--
--
Sep 30, 2025
BC Global Opportunities IX LP
4.37M
5.46%
+3.27M
+296.89%
Sep 04, 2025
Omega Fund Management, LLC
3.29M
4.11%
+3.29M
--
Sep 30, 2025
Wellington Management Company, LLP
2.96M
3.7%
+2.78M
+1504.24%
Sep 30, 2025
Alphabet, Inc.
2.82M
3.53%
+2.82M
--
Sep 30, 2025
EcoR1 Capital, LLC
2.82M
3.53%
+2.82M
--
Sep 30, 2025
Enavate Sciences GP, LLC
2.63M
3.28%
+2.63M
--
Sep 30, 2025
Citadel Advisors LLC
2.54M
3.17%
+1.11M
+77.84%
Sep 30, 2025
View more
Related ETFs
Updated: Tue, Dec 9
Updated: Tue, Dec 9
Name
Proportion
Tema Oncology ETF
0.26%
Schwab U.S. Small-Cap ETF
0.01%
Schwab U.S. Broad Market ETF
0%
iShares Health Innovation Active ETF
0%
Tema Oncology ETF
Proportion0.26%
Schwab U.S. Small-Cap ETF
Proportion0.01%
Schwab U.S. Broad Market ETF
Proportion0%
iShares Health Innovation Active ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of BridgeBio Oncology Therapeutics Ord Shs?
The top five shareholders of BridgeBio Oncology Therapeutics Ord Shs are:
Cormorant Asset Management, LP holds 17.88M shares, accounting for 22.35% of the total shares.
BridgeBio Pharma, Inc. holds 13.81M shares, accounting for 17.43% of the total shares.
Deerfield Management Company, L.P. holds 4.89M shares, accounting for 6.11% of the total shares.
BC Global Opportunities IX LP holds 4.37M shares, accounting for 5.46% of the total shares.
Omega Fund Management, LLC holds 3.29M shares, accounting for 4.11% of the total shares.
Cormorant Asset Management, LP holds 17.88M shares, accounting for 22.35% of the total shares.
BridgeBio Pharma, Inc. holds 13.81M shares, accounting for 17.43% of the total shares.
Deerfield Management Company, L.P. holds 4.89M shares, accounting for 6.11% of the total shares.
BC Global Opportunities IX LP holds 4.37M shares, accounting for 5.46% of the total shares.
Omega Fund Management, LLC holds 3.29M shares, accounting for 4.11% of the total shares.
What are the top three shareholder types of BridgeBio Oncology Therapeutics Ord Shs?
The top three shareholder types of BridgeBio Oncology Therapeutics Ord Shs are:
Cormorant Asset Management, LP
BridgeBio Pharma, Inc.
Deerfield Management Company, L.P.
Cormorant Asset Management, LP
BridgeBio Pharma, Inc.
Deerfield Management Company, L.P.
How many institutions hold shares of BridgeBio Oncology Therapeutics Ord Shs (BBOT)?
As of 2025Q4, 73 institutions hold shares of BridgeBio Oncology Therapeutics Ord Shs, with a combined market value of approximately 54.44M, accounting for 68.05% of the total shares. Compared to 2025Q3, institutional shareholding has increased by 0.02%.
What is the biggest source of revenue for BridgeBio Oncology Therapeutics Ord Shs?
In --, the -- business generated the highest revenue for BridgeBio Oncology Therapeutics Ord Shs, amounting to -- and accounting for --% of total revenue.
